Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/drug therapy , Coronary Disease/drug therapy , Dibenzazepines/therapeutic use , Aged , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/physiopathology , Coronary Disease/complications , Coronary Disease/physiopathology , Female , Heart Conduction System/drug effects , Heart Conduction System/physiopathology , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Male , Middle Aged , TabletsABSTRACT
Palpitin, an agent of the disopyramide series, was evaluated for its antiarrhythmic potency in the treatment of ventricular and supraventricular arrhythmias and for its effects of ECG and central hemodynamic parameters in 108 patients (91 had coronary heart disease, 8 presented with postmyocardial cardiosclerosis, 5 had hypertensive disease, and 4 suffered from neurocirculatory dystonia). 24-hour ECG monitoring and echocardiography were employed in the study. It was concluded that the drug possessed a high antiarrhythmic potency. No substantial changes were found in the mean values of echocardiographic parameters, as well as of atrioventricular and intraventricular conduction.
Subject(s)
Arrhythmias, Cardiac/drug therapy , Disopyramide/analogs & derivatives , Heart/drug effects , Hemodynamics/drug effects , Adolescent , Adult , Aged , Cardiac Complexes, Premature/drug therapy , Disopyramide/pharmacology , Echocardiography , Electrocardiography, Ambulatory , Female , Humans , Male , Middle AgedABSTRACT
The influence of antiarrhythmic drugs (oral lidocaine, palpitine, Etacizine) on blood platelet aggregation and prostaglandin metabolites was studied in 91 patients with ischaemic heart disease. Lidocaine showed a positive, Etacizine a negative, and palpitine no effect on platelet aggregation. There was no uniform effect of lidocaine on prostaglandin metabolites; it increased the prostacycline and decreased the thromboxane levels. Palpitine increased both prostacyclin and thromboxane levels, whereas Etacizine decreased both metabolites, especially prostacyclin.
Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Coronary Disease/physiopathology , Platelet Aggregation/drug effects , Prostaglandins/metabolism , Adult , Aged , Angina Pectoris/drug therapy , Coronary Disease/drug therapy , Disopyramide/analogs & derivatives , Disopyramide/therapeutic use , Female , Humans , Lidocaine/therapeutic use , Male , Middle Aged , Nitroglycerin/administration & dosage , Phenothiazines/therapeutic use , Platelet Aggregation InhibitorsSubject(s)
Disopyramide/analogs & derivatives , Hemostasis/drug effects , Adolescent , Adult , Aged , Blood Platelets/drug effects , Blood Vessels/drug effects , Coronary Disease/blood , Coronary Disease/drug therapy , Disopyramide/therapeutic use , Drug Evaluation , Female , Humans , Male , Middle Aged , Plasma/drug effectsABSTRACT
Clinical efficiency of the antiarrhythmic agent palpitin used for the treatment of ventricular and supraventricular extra-systole was assessed in 94 coronary patients, using Holter's ECG monitoring, electrophysiologic studies and rheographic control; reliable evidence in favor of the drug high antiarrhythmic efficiency was obtained.
